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Abstract
Background: Linear growth and final height are reported as normal in congenital hypothyroid patients in the
neonatal screening era.
Methods: We evaluated the final height in 215 patients with congenital hypothyroidism to assess if it improved
over the last 2 decades.
Results: Final height (-0.1 ± 1.0 SDS) was higher than target height (-0.8 ± 1.0 SDS, p < 0.001) and not different
among the 4 quartiles for birthdate. It was correlated with target height (r2 = 0.564, p < 0.001) and height at puberty
onset (r2 = 0.685, p < 0.001), but not with age at diagnosis or the starting LT4/kg/day dose. The curve fitting analysis
showed that the age at diagnosis progressively decreased during the 20-year study period, while the target height
and the starting LT4/kg/day increased. Final height was not affected by the birthdate, the age at diagnosis, the
starting LT4 dose.
Conclusions: The final height is higher than the target height, but despite the improvement in the screening and
the treatment, it did not improve over the last 20 years. These findings are in keeping with the described secular
trend and suggest that earlier diagnosis and replacement therapy do not significantly modify final height in these
patients.
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Introduction
Congenital hypothyroidism (CH) is the most frequent
endocrine disease in childhood which causes mental
delay and short stature if untreated [1, 2]. The neonatal
screening allows early diagnosis while appropriate treat-
ment with replacement dose of levo-thyroxine (LT4)
prevents its consequences. Since 70s, when neonatal
screening for CH was established in most of the devel-
oped Countries, the mean age at diagnosis has been pro-
gressively reduced and the auxological and neurological
outcomes significantly improved.
Linear growth, onset and progression of puberty, pu-
bertal growth and final height (FH) are reported as ra-
ther normal in patients diagnosed thorough the
screening, and the target height (TH) is the most im-
portant factor determining linear growth [3–8]. The
neurodevelopmental outcome is greatly superior in in-
fants detected through neonatal screening than in those
diagnosed after the onset of clinical signs, and CH sever-
ity at diagnosis, the initial LT4 dose and the timing of
normalization of thyroid function are the main factors to
prevent mental delay [9–16]. However, even if the neo-
natal screening programs ensure the prompt initiation of
the therapy and the neurodevelopmental outcome can
be considered generally normal, some problems in rela-
tion to mental outcome are still reported in follow-up
studies [17, 18]. Recent papers focusing on educational
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attainment, cognitive and motor outcome failed to show
that in young CH adults diagnosed in the screening era
the age at starting treatment plays a key-role in educa-
tional attainment [19, 20].
The effects of the improvement in early diagnosis and
treatment on neurodevolopmental outcome have been
clearly documented by several studies [21], while this re-
lationship has not yet been proved as concern growth
and pubertal outcome.
A significant relationship between the age at the start
of treatment and FH was demonstrated [5], but it was
not confirmed by the correlation analysis performed in a
larger study population [7].
The studies focusing on linear growth were run in pa-
tients diagnosed in the early CH screening era, i.e. late
70s and 80s, when the age at starting treatment was
higher and the starting LT4 dose lower than in 90s and
later on. Prompted by these data, we evaluated the FH
in a large cohort of patients with permanent CH aiming
to evaluate whether the earlier diagnosis and the higher
L-T4 starting dose lead to an improvement in growth
and pubertal outcome over the last 2 decades.
Methods
Patients
In this multicentre observational study, we enrolled 215
patients (152 females, 63 males) with permanent CH,
born at full term after an uncomplicated pregnancy be-
tween 1980 and 2000 and referred to our Hospitals be-
cause of positive neonatal screening. The diagnosis was
confirmed by serum TSH, T4 and/or free T4 levels at a
mean age of 25.1 ± 10.5 days. The aetiology was assessed
in all the patients by a 99mTc-pertechnetate thyroid scan
performed in the same morning of the blood sampling
for confirmatory diagnosis. An additional thyroid ultra-
sound was performed in all the patients with athyreosis.
Forty-four patients (20.5 %) showed an in situ thyroid,
109 (50.7 %) an ectopic gland, 62 (28.8 %) were athyreo-
tic. On the day of diagnosis, oral treatment with LT4
was started at a mean dose of 8.8 ± 2.9 mcg/kg/day. Pa-
tients with transient CH, or not identified by the screen-
ing program, and CH patients with conditions that
could affect growth (celiac disease, small for gestational
age, chromosopathy, etc.) or with low compliance to the
replacement treatment during the follow up were ex-
cluded from the study. The study was approved by the
local Ethic Committee.
Follow-up
The patients assumed regularly the daily LT4 dose
20-30 min before the first meal of the day. The dose
was titrated on the basis of clinical and biochemical
findings in order to maintain a satisfactory health
condition and to keep the TSH and the free T4
within the normal limits. A complete physical and
auxological evaluation, and hormonal levels assays
were performed regularly in keeping with guidelines.
FH was defined as growth velocity < 1 cm/year. The
follow-up period at FH attainment was 16.1 ±
1.7 years.
We recorded age and LT4 dose at diagnosis, age and
height at puberty onset, TH and FH. Patients’ and their
parents’ standing height was measured by a wall-
mounted Harpenden Stadiometer. TH was calculated as
follow: (mother’s height + father’s height) + 6.5 cm (if
males) or - 6.5 cm if females [22]. The onset of puberty
was defined in males by testicles volume 4 ml and in fe-
males by breast development 2nd Tanner stage. The on-
set of puberty was defined as normal if between 8.0 and
13.4 yrs in females and 9.0–14.0 yrs in males [23]. Hor-
monal assays were performed using commercial kits by
radioimmunoassay until 1995 and by immunofluores-
cence assay thereafter.
Statistical analysis
Height was calculated as standard deviation score (SDS)
in keeping with the Italian standard growth charts [24].
The rate of overweight and obesity was calculated on the
basis of the Italian growth charts [24]. The difference be-
tween FH and TH was calculated both in cm and in SDS
and defined as Δheight. To further evaluate if FH in-
creased over the years, the patients were classified into 4
subgroups on the basis of the quartile for birthdate. Data
were expressed as mean ± standard deviation (SD) and
the statistical analysis was performed with SPSS com-
puter software for Windows (version 17.5, SPSS Inc.).
The t-student test for paired data was used to compare
FH, TH, and H at puberty onset. The Analysis of Vari-
ance (ANOVA) and the Chi-Square test were used to
compare mean values and frequencies among groups, re-
spectively. The correlation coefficients were determined
by the Pearson’s test. The prediction model of FH was
developed by means of multiple linear regression ana-
lysis with a stepwise method fitted by least squares with
the following variables: 1) TH SDS; 2) H at onset of pu-
berty; 3) age at diagnosis; 4) starting LT4/kg/day. The
curve fitting regression analysis with linear model was
used to evaluate the relationship between parameters.




The puberty onset occurred in males at 11.4 ± 1.2 years,
in females at 10.4 ± 1.1 years. It was within the normal
limits for age in 212 (98.6 %) patients, one male showed
anticipated puberty (8.5 years), and 1 male and 1 female
delayed puberty (14.5 and 13.9 years, respectively). The
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age at puberty onset was not different among the four
quartiles for birthdate in males and in females. Height at
puberty onset was -0.1 ± 1.0 SDS and the height gain
during puberty was -0.1 ± 0.8 SDS, both of them not dif-
ferent between the 3 etiological groups or between males
and females (Table 1). Height at puberty onset was sig-
nificantly higher than TH (p < 0.001) (Fig. 1).
Height
Final height
FH (-0.1 ± 1.0 SDS) was significantly higher than TH
(-0.8 ± 1.0 SDS, p < 0.001) (Table 1, Fig. 1) and it was not
different as compared to height at puberty onset. FH
was 172.5 ± 6.2 cm (-0.3 ± 1.0 SDS) in males and 160.0 ±
6.2 cm (-0.1 ± 1.0 SDS) in females, both of them signifi-
cantly higher than TH (p < 0.001 in both gender). The
Δheight was 2.5 ± 5.6 cm in males and 2.3 ± 5.7 cm in fe-
males. FH, TH, and Δheight were not different among
patients with in situ thyroid, or athyreosis, or ectopic
gland (Table 1). FH and Δheight were was not different
between males and females, while TH was lower in
males than in females (-1.0 ± 0.8 vs -0.7 ± 1.0, p = 0.009)
(Table 1).
Quartiles analysis
In the forth quartile, the age at diagnosis was lower than
in the first (p < 0.001) and in the second one (p < 0.005),
and the starting LT4 was higher than in the other 3
quartiles (p < 0.001) (Table 2). FH was not different
among the 4 quartiles, while the TH was significantly
higher in the forth quartile than in the first (p = 0.006).
Correlation and regression analysis
FH was significantly correlated with TH (r2 = 0.564,
p < 0.001) and height at puberty onset (r2 = 0.685, p <
0.001), but not with age at diagnosis or the starting LT4/
kg/day dose. The best equation predicting FH was FH
SDS = 0.175 + 0.55 H at onset of puberty SDS + 0.328 TH
SDS (p < 0.001). This model explains 75.2 % of FH vari-
ability, with a standard error of 0.7 SDS. In our model, H
at onset of puberty is the most important predictor, ac-
counting for 68.5 % of FH variability itself. TH accounts
for 56.4 % of FH variability. Both the age at diagnosis and
the starting LT4/kg/day were excluded by the statistical
analysis in the prediction model.
The curve fitting analysis showed that the age at diag-
nosis progressively decreased (r2 = 0.083, p < 0.001),
while the TH and the starting LT4/kg/day progressively
increased (r2 = 0.200, p < 0.001, and r2 = 0.033, p = 0.007,
respectively) over the study period. FH was not affected
by the birthdate (Fig. 2), the age at diagnosis (Fig. 3), nor
the starting LT4 replacement dose.
Overweight and obesity
Sixty-three patients (29.3 %) were overweight and 16
(7.4 %) obese, without any statistical difference on the
basis of gender, aetiology, nor quartile for birthdate.
Discussion
Since it was established in 70s, the CH screening was
significantly improved year by year and the current
guidelines [16] suggest a starting dose of 10-15 μg/kg/
day of LT4, higher than in the past, to prevent the
Table 1 The table displays the population size and mean ± standard deviation of age at diagnosis, LT4 starting dose, height (H) at
puberty onset, heigth gain during puberty, final height (FH), and target height (TH) in the recruited patients classified as etiology
and gender. a vs males: p = 0.009
In situ thyroid Ectopic gland Athyreosis Males Females Study cohort
Number of patients (%) 44 (20.5 %) 109 (50.7 %) 62 (28.8 %) 63 (29.3 %) 152 (70.7 %) 215 (100 %)
Age at diagnosis (days) 25.4 ± 10.1 24.1 ± 6.8 26.6 ± 15.1 24.7 ± 11.7 25.2 ± 10.0 25.1 ± 10.5
LT4 starting dose (μg/kg/day) 8.9 ± 2.8 8.8 ± 3.0 8.6 ± 3.0 8.1 ± 2.7 9.1 ± 3.0 8.8 ± 2.9
H at puberty onset (SDS) -0.3 ± 1.0 0.1 ± 0.9 -0.2 ± 0.9 -0.1 ± 0.9 -0.1 ± 1.0 -0.1 ± 1.0
Pubertal H gain (SDS) 0.1 ± 0.7 -0.2 ± 0.8 0.1 ± 0.8 -0.2 ± 0.8 0.0 ± 0.8 -0.1 ± 0.8
FH (SDS) -0.2 ± 1.0 -0.1 ± 1.0 -0.1 ± 1.1 -0.3 ± 1.0 -0.1 ± 1.0 -0.1 ± 1.0
TH (SDS) -1.0 ± 1.0 -0.8 ± 0.9 -0.7 ± 1.0 -1.0 ± 0.8 -0.7 ± 1.0a -0.8 ± 1.0
Data cohort according to aetiology and gender
Fig. 1 HEIGHT. The figure displays the main values of final height
(FH), height (H) at puberty onset, and target height (TH) in males,
females, and in whole study cohort. * vs FH: p < 0.001. * vs H at
puberty onset: p < 0.001
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sequelae due to thyroid hormones deficiency. Nowadays,
CH patients are more properly treated and it is well ac-
knowledged that the replacement LT4 dose beyond the
neonatal period is different on the basis of CH aetiology
[25–27].
Neonatal screening programs for CH have been highly
successful over the last years in improving both cogni-
tive and growth outcome.
We had already shown that FH in CH patients is nor-
mal and significantly higher than TH, and that these 2
parameters are very well correlated among them, with-
out any effect exerted by the age at the start of treatment
[7]. However in a previous paper, Bain et al [5] showed
that the patients with a positive Δheight had a signifi-
cantly younger mean age at the start of treatment than
children with a negative Δheight. However, the present
study confirms our previous data, that the age at the
start of treatment does not exert any effect on growth
outcome.
To assess if the final height improved over the last 20-
years, we divided patients on the basis of birthdate, in
quartiles, and we also evaluated all data through the fit-
ting curve analysis. Our data confirmed that FH in CH
patients is normal and significantly higher than TH, and
that these 2 parameters were very well correlated among
them. The age at the start of treatment did not play any
role on FH, which was not different among the 4 quar-
tiles of birthdate. The regression analysis confirmed that
FH did not change over the 20-year study period (Fig. 2),
while TH slowly increased, thus suggesting that the
secular trend in height accounts to a large extent for our
findings. Since 1850 there has been a positive secular
trend in height among European populations [28–30]. In
many European countries and in Italy as well, this secu-
lar trend slowed down or even reached a plateau since
the 80s/90s [30–34] whereas in other Countries, like
Belgium, Spain, and Portugal, average heights might still
increase [32]. This trend well fits with our data: TH was
assessed on parents born in 50s, 60s, and 70s, when the
height steadily raised up, while the siblings were born
when the secular trend slowed down or reached a
Table 2 The Table displays mean ± standard deviation of age at diagnosis, starting dose of levo-thyroxine (LT4), height (H) at
puberty onset, final height (FH), and target height (TH) in the recruited patients divided in quartiles on the basis of birthdate. a vs 4
th quartile p ≤ 0.001; b vs 4 th quartile p≤ 0.005; c vs 1st quartile and vs 2nd quartile p < 0.05
1st quartile, 54 patients
(18-Mar-80/9-Nov-84)
2nd quartile, 54 patients
(30-Nov-84/23-Jun-90)
3rd quartile, 54 patients
(29-Jul-90/27-Jan-95)
4th quartile, 53 patients
(27-Feb-95/9-Dec-00)
Age at diagnosis (days) 28.5 ± 11.9 a 27.6 ± 12.6 b 23.4 ± 7.3 20.8 ± 7.4
Starting LT4/kg/day (μg) 7.5 ± 2.4 a 7.6 ± 2.3 a 8.9 ± 2.4 a, c 11.2 ± 3.0
H at puberty onset (SDS) -0.2 ± 1.0 0.0 ± 1.0 0.0 ± 1.0 -0.1 ± 0.8
FH (SDS) -0.1 ± 1.1 0.0 ± 1.1 -0.1 ± 1.0 -0.3 ± 0.9
TH (SDS) -1.0 ± 0.9 a -0.9 ± 1.2 -0.7 ± 0.8 -0.5 ± 0.9
Data according to quartile for birthdate
Fig. 2 FH AND BIRTHDATE. The figure displays the linear relationship
between final height (FH) and birthdate (p = ns)
Fig. 3 FH AND AGE AT DIAGNOSIS. The figure displays the linear
relationship between final height (FH) and age at diagnosis (p = ns)
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plateau. Reasonably, FH does not improve over the 20-
year study in keeping with the secular trend. The lack of
relationship between the birthdate and FH and between
the day on which treatment was initiated and FH sug-
gests that this outcome is not affected by the timing of
treatment initiation, at least under the condition of CH
screening and starting treatment described in this paper.
While for mental delay it is supposed that some differ-
ences do in fact exist in relationship with age at diagno-
sis [21], our data suggest that the earlier diagnosis does
not influence the height outcome.
We confirm that TH and height at puberty onset are
the most important factors affecting FH in CH patients.
These patients are taller than TH by 2-2.5 cm, in agree-
ment with data previously reported [7]. The height gain
found in this study seems in keeping with the described
secular trend of 0.6-1 cm/year [35, 36].
The puberty onset occurred within the normal limits
in almost all the patients recruited, confirming previous
data [3–8]. We did not find any difference between FH
and height at puberty onset, suggesting that the pre-
pubertal and the pubertal height gain were similar to the
normal population.
The prevalence of overweight was higher than the pre-
vious French data reported by Léger et al. [20], while the
prevalence of obesity was comparable. We did not re-
cruit a control group the evaluate if the prevalence of
overweight/obesity was higher than in the normal popu-
lation, but we think that our findings are in keeping with
the Italian data reported by the Italian Health System
(http://www.epicentro.iss.it/problemi/obesita/
EpidItalia.asp).
The most robust point of this study is the 20-year study
period. There are no reports on a so long period allowing
us to proper evaluate any change in FH in CH patients
born in 80s and 90s. Our data include patients born in the
early period of the CH screening program when the diag-
nosis was done later and the starting treatment based on
lower dose of LT4. Nowadays, the treatment starts earlier,
with higher doses of LT4, resulting in the early
normalization of thyroid hormone levels. The interpret-
ation of our findings should take into consideration the
differences in age at diagnosis and in the starting dose and
therefore our results may be relevant to infants diagnosed
with CH today to a lower extent than expected.
In conclusion, age at puberty onset, linear growth dur-
ing puberty and final height are normal in congenital
hypothyroid patients diagnosed after neonatal screening.
The final height is higher than the target height. Despite
the large improvement in the screening strategy and the
treatment approach final height did not improve in pa-
tients born in 80s and 90s, suggesting that the early
diagnosis and the treatment strategy do not seem to
affect the final height.
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